Rheumatic Fever
Acute rheumatic fever (ARF) is a sterile, systemic autoimmune inflammatory disease that develops after an upper respiratory infection with group A beta-hemolytic streptococcus (GAS, most often Streptococcus pyogenes). ARF is the textbook example of molecular mimicry. During a GAS infection, the immune system makes antibodies against the M protein in the bacterial cell wall. Because this protein closely resembles some of the body's own structures, those antibodies and cytotoxic T cells cross-react and turn on the body's own tissues. The resulting autoimmune inflammation spreads through connective tissue and concentrates in the heart (myosin fibers), the joints (synovium), the skin (subcutaneous fat), and the central nervous system (basal ganglia cells).
At Haute-Derma, we approach acute rheumatic fever with a strict, prevention-first mindset. Unlike other chronic forms of arthritis, ARF can be prevented if the initial throat infection is treated properly. What makes it more concerning is that the joint inflammation, though dramatic, settles on its own, while the heart inflammation (carditis) progresses quietly and can leave permanent scarring of the heart valves (rheumatic heart disease). Our goals are to confirm the diagnosis precisely, shut down the autoimmune reaction early, and put a rigorous relapse-prevention plan in place to protect both your heart and your joints.
Our Approach to Treating Acute Rheumatic Fever
Because acute rheumatic fever affects several organs and can leave serious heart damage, Haute-Derma follows a strategy of "eradicate the bacteria, stop the carditis":
- Revised Jones criteria: We apply the latest Jones criteria strictly, stratifying patients by epidemiological risk to reach a confirmed diagnosis quickly and avoid missing subclinical disease.
- Echocardiographic screening for silent carditis: Every patient with suspected or confirmed ARF has a color Doppler echocardiogram to catch myocarditis or valve regurgitation early, even before a murmur can be heard with a stethoscope.
- Long-term relapse prevention: After the acute episode, we open a follow-up record and set a strict antibiotic prophylaxis schedule to minimize the risk of streptococcal reinfection worsening valve damage.
How We Diagnose Acute Rheumatic Fever at Haute-Derma
At Haute-Derma, a diagnosis of ARF requires evidence of a preceding group A streptococcal infection together with clinical and laboratory findings that meet the Jones criteria:
Evidence of Group A Streptococcal Infection (Required)
- A positive throat culture or a positive rapid streptococcal antigen test.
- Or raised antistreptococcal antibodies in the blood (an ASO (antistreptolysin O) titer well above the normal range, or a rising titer between two samples).
Major Criteria
- Migratory polyarthritis: The hallmark of rheumatic fever. Large joints (knees, ankles, elbows, wrists) suddenly become swollen, hot, red, and very painful. Just as one joint is at its worst, it settles and the inflammation "moves" to another large joint. The arthritis responds remarkably quickly to anti-inflammatory drugs.
- Carditis: The most dangerous complication, which can involve all three layers of the heart (pancarditis). Echocardiography can reveal endocarditis damaging the valves (most often the mitral and aortic valves), myocarditis, or pericardial effusion.
- Sydenham chorea: A late neurological feature caused by antibodies targeting the basal ganglia. The child makes sudden, rapid, purposeless involuntary movements of the face and limbs, along with muscle weakness and mood or behavioral changes.
- Erythema marginatum: A distinctive but rare rash. Pale pink patches with wavy edges spread outward into rings with paler centers. They appear mainly on the trunk and upper limbs, almost never on the face, and do not itch.
- Subcutaneous nodules: Firm, painless, pea-sized nodules that move under the skin, usually over bones or tendons at the elbows, knees, and wrists. They tend to appear alongside severe carditis.
Minor Criteria
- Pain in several joints (arthralgia) without swelling, warmth, or redness.
- Fever (usually above 38.5°C).
- Raised blood markers of inflammation: a sharply elevated erythrocyte sedimentation rate (ESR) or high CRP.
- A prolonged PR interval on the electrocardiogram (ECG), reflecting first-degree atrioventricular block from myocarditis.
How Acute Rheumatic Fever Is Treated at Haute-Derma
Our treatment plan for acute rheumatic fever aims to eradicate the bacteria, shut down the systemic autoimmune reaction, and protect the heart valves:
Eradicating Group A Streptococcus
- As soon as the diagnosis is confirmed or strongly suspected, the patient receives a course of bactericidal antibiotics by injection or by mouth (preferably penicillin, or an alternative such as a macrolide for those allergic to penicillin). The aim is to clear any remaining streptococcal antigen from the throat and remove the trigger that keeps the immune system making misdirected antibodies.
Systemic Anti-Inflammatory Therapy (Stopping the Autoimmune Reaction)
- Arthritis alone or mild carditis: High-dose aspirin (salicylates) or potent NSAIDs. The arthritis of rheumatic fever responds dramatically to aspirin, and the migrating pain and swelling clear quickly once treatment starts.
- Severe carditis (with heart failure or an enlarged heart): Instead of NSAIDs, the doctor prescribes systemic corticosteroids (such as prednisolone or methylprednisolone) to quickly calm inflammation of the heart muscle and lining and reduce the risk of later valve scarring and retraction. The dose is tapered gradually, with aspirin overlapping before the steroid is stopped.
Long-Term Relapse Prevention (Secondary Prophylaxis)
This is the single most important step for the patient's future. Because the immune system now carries a "faulty memory," any later streptococcal throat infection can set off a new attack and damage the heart valves further:
- Patients receive regular preventive antibiotic injections, usually long-acting benzathine benzylpenicillin given deep into the muscle every 3–4 weeks.
- How long prophylaxis continues depends on age and the extent of heart involvement: at least 5 years if there was no carditis, until age 21 or longer if there was carditis without lasting valve damage, and possibly for life if there is severe residual valve disease.
